Cambridge Healthtech Institute’s 22nd Annual

Recombinant Protein Expression and Production
( 重組蛋白質的表現和製造 )

Enhancing Expression, Performance, and Process


Part of the Biotherapeutic Expression & Production pipeline

Great strides have been made in the expression, production, and purification of biotherapeutics. However, hurdles remain to improving the quantity and quality of the efficient expression and production of these valuable biomolecules while minimizing time and cost. There is a greater demand for higher-throughput expression and purification, as well as more flexible expression platforms. Unfortunately, there is no “universal” production system which can guarantee high yields of recombinant protein, particularly as every biomolecule causes issues in terms of its own expression. Cambridge Healthtech Institute’s 22nd Annual Recombinant Protein Expression and Production conference explores the newest data and innovations relating to the best choices in hosts/systems, as well as ways to “rescue” existing systems and make them work more effectively to produce the quality and quantity of the desired biotherapeutic.

Preliminary Agenda


FEATURED PRESENTATION: Analysis of the Immunoglobulin G (IgG) Secretion Efficiency in Recombinant Chinese Hamster Ovary (CHO) Cells by using Citrine-Fusion IgG

Takeshi Omasa, PhD, Professor, Department of Material and Life Science, Graduate School of Engineering, Osaka University

Novel Prediction Tool to Evaluate Synonymous Changes in Recombinant Therapeutic Proteins

Nobuko Katagiri, PhD, Research Biologist, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, CBER, FDA

Recombinant Protein Production in Research at Novo Nordisk

Brian Vandahl, PhD, Corporate Vice President, Recombinant Technologies, Global Research Technologies, Novo Nordisk A/S

Recent Advances in Screening and Production of Recombinant Proteins in Plants and Plant Cells

Johannes Buyel, Dr-Ing, Head, Integrated Production Platforms, Fraunhofer Institute for Molecular Biology and Applied Ecology IME


Attenuated Glutamine Synthetase as a Selection Marker in CHO Cells to Efficiently Isolate Highly Productive Stable Cells for the Production of Antibodies and Other Biologics

Zhiwei Song, PhD, Principal Scientist & Lead Principal Investigator, Expression Engineering, Bioprocessing Technology Institute, A*STAR

Antibody Production Using an Inducible CHO Cell Line: Process Development and Intensification

Olivier Henry, PhD, Associate Professor, Chemical Engineering, Polytechnique Montréal


Engineering Cells for Heparin and Heparan Sulfate Production

Charles A. Glass, PhD, President & CSO, TEGA Therapeutics, Inc.

Scalable Production and Purification of Single-Stranded DNA

Tyson Shepherd, Research Associate, Mark Bathe Laboratory, Department of Biological Engineering, Massachusetts Institute of Technology

* 活動內容有可能不事先告知作更動及調整。

Choose your language